Complete Remission of Nephrotic Syndrome of Hepatitis B Virus-associated Membranous Glomerulopathy After Lamivudine Monotherapy
|
|
- Jessica Lindsey
- 5 years ago
- Views:
Transcription
1 CASE REPORT Complete Remission of Nephrotic Syndrome of Hepatitis B Virus-associated Membranous Glomerulopathy After Lamivudine Monotherapy Tang-Wei Chuang, 1 Chao-Hung Hung, 1 * Shun-Chen Huang, 2 Chuan-Mo Lee 1 We present the case of a 22-year-old male with chronic hepatitis B virus (HBV) infection, who developed nephrotic syndrome and had complete remission after lamivudine monotherapy. Renal biopsy showed membranous glomerulopathy, and the serum titer of HBV DNA increased to 1,130,000 copies/ml. As symptomatic therapy with angiotensin converting enzyme inhibitors did not improve the nephrotic syndrome, lamivudine 100 mg per day was started. His alanine aminotransferase level normalized 2 months after treatment, then hepatitis B e antigen seroconversion developed and serum HBV DNA became undetectable. His proteinuria improved subsequently and his leg edema disappeared completely 6 months after treatment. Neither hepatitis nor nephrotic syndrome had relapsed by month 13 when he came for follow-up. This suggests that lamivudine monotherapy may induce and maintain complete remission of membranous glomerulopathy associated with hepatitis B. [J Formos Med Assoc 2007;106(10): ] Key Words: hepatitis B virus, lamivudine, membranous glomerulonephritis, nephrotic syndrome According to clinical, epidemiologic and immunologic evidence, chronic hepatitis B virus (HBV) infection is strongly associated with the occurrence of membranous glomerulopathy (MN), particularly in children. 1 The majority of pediatric patients with HBV-related MN have a good prognosis in terms of the preservation of renal function, and there is a high rate of spontaneous remission. 2 In contrast, the clinical course of HBV-related MN in adults is not benign. Regardless of treatment, this disease has a slow but relentlessly progressive course in approximately one third of adult patients. 3 Steroids and other immunosuppressive therapies that are the mainstay of treatment for idiopathic forms of MN may cause more harm than good by enhancing viral replication and precipitating hepatitis flares in HBV-related MN. Interferon (IFN)-α, while reported to be useful in children, has produced disappointing results in Chinese adult subjects. 3 Recently, lamivudine, a nucleoside analog inhibitor of HBV DNA polymerase, has been shown to have advantages over IFN for HBV treatment because of its having fewer side effects and an oral route of administration. Here, we report the case of an adult patient with chronic hepatitis B who developed MN with nephrotic syndrome and who experienced complete remission after lamivudine monotherapy Elsevier & Formosan Medical Association Division of Hepatogastroenterology, Department of Internal Medicine, and 2 Department of Pathology, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan. Received: August 24, 2006 Revised: February 9, 2007 Accepted: April 10, 2007 *Correspondence to: Dr Chao-Hung Hung, Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan. chh4366@yahoo.com.tw J Formos Med Assoc 2007 Vol 106 No
2 T.W. Chuang, et al Case Report A 22-year-old Taiwanese male patient who had a history of chronic HBV infection lasting for several years was regularly followed-up at the local medical clinic. He was found to be positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antibody (anti-hbe Ab), and negative for hepatitis B e antigen (HBeAg). He had an increased serum level of aspartate aminotransferase (AST) of 268 U/L and alanine aminotransferase (ALT) of 239 U/L in May Three months later, due to progressive edematous changes in bilateral legs, he was referred to our outpatient department. Laboratory analyses showed the following: serum AST of 99 U/L, ALT of 119 U/L, creatinine of 0.9 mg/ dl, and decreased albumin level of 1.6 g/dl. Serologically, his anti-hbe Ab was positive. His HBeAg, immunoglobulin (Ig) M antibody to hepatitis B core, IgM antibody to hepatitis A virus, and antibody to hepatitis C virus were all negative. His serum HBV DNA as determined by sensitive polymerase chain reaction assay (COBAS Amplicor HBV Monitor; Roche Diagnostics, Branchburg, NJ, USA) was 1,130,000 copies/ml. Urinalysis showed proteinuria 500 mg/dl by dipstick. His renal and abdominal ultrasound examinations were normal. He was admitted to our hospital for a renal biopsy in September Physical examination was unremarkable except for the extremities which showed severe pitting edema. A repeat data collection showed decreased albumin level of 1.1 g/dl, high cholesterol level of 370 mg/dl and urine total protein loss of 6.0 g/day. His renal biopsy displayed diffusely thickened and rigid capillary walls. Spikes were identified in a few segments by silver stain. On immunofluorescence study, IgG, C3 and C4 were positive along the capillary loops in a granular pattern. IgM was also present, but to a lesser intensity. On electron microscopy, the glomeruli showed diffuse foot process effacement of the epithelial cells. The capillary loops were irregularly thickened by many small and large electron-dense deposits on the subepithelial side of the basement membrane, compatible with membranous nephropathy stage II to III (Figure 1). Fosinopril 10 mg/day was given initially, which was then changed to valsartan 40 mg/day and albumin infusion combined with diuretic therapy (25 mg spironolactone, three times daily) for the edema in his legs. In October 2003, his bilateral leg edema persisted without any clinical improvement. Repeat data collection showed that his AST and ALT levels were still elevated (128 U/L and 84 U/L, respectively), and HBeAg was positive. Serum albumin had decreased to 0.7 g/dl. He began treatment with lamivudine 100 mg/day after giving informed consent. His ALT levels gradually decreased and normalized 2 months after the start of treatment, in which HBeAg seroconversion developed and his serum HBV DNA became negative (< 200 copies/ ml). His serum albumin level gradually increased and was > 3.0 g/dl after 9 months of therapy. The pitting edema in both legs disappeared completely 6 months after lamivudine treatment, and diuretics were not necessary thereafter. Lamivudine was discontinued after 18 months of therapy. By month 13 after lamivudine treatment had been stopped, the patient remained free of edema, with normal ALT, albumin and cholesterol levels and no detectable HBV DNA in his serum. His daily urine protein loss had decreased to 0.6 g/day and 0.02 g/ day at the end of treatment and at follow-up, respectively (Figure 2). Discussion A variety of extrahepatic manifestations is observed in patients with both acute and chronic viral hepatitis. A previous study has shown that approximately 16% of chronic hepatitis B patients have clinical extrahepatic manifestations, mainly sensorimotor deficiency (5%), sicca syndrome (3%), myalgia (3%), glomerulonephritis (3%), and arthralgia-arthritis (3%). 4 MN is an uncommon but well-documented extrahepatic manifestation of HBV infection. The diagnosis of HBV-associated MN is usually established by serologic evidence of persistent HBV infection, the 870 J Formos Med Assoc 2007 Vol 106 No 10
3 Lamivudine for HBV nephrotic syndrome A B C D Figure 1. (A) Glomeruli show diffusely thickened and rigid capillary walls (hematoxylin & eosin, 66 ). (B) Silver stain shows spikes in a few segments (periodic acid methenamine silver stain, 330 ). (C) Electron microscopy shows irregularly thickened capillary walls with many small and large electron-dense deposits on the subepithelial side of the basement membrane (4000 ). (D) Viral-like particles (arrows) appearing as clusters of round to ovoid structures, nm in diameter and of varying density, were seen in some electron-dense deposits. Albumin (g/dl) Aug-03 Sep-03 Lamivudine Albumin (g/dl) ALT (U/L) TDPL (g/day) Oct-03 Nov-03 Dec-03 Jan-04 Feb-04 Mar-04 Apr-04 May-04 Jun-04 Jul-04 Aug-04 Sep-04 Oct-04 Nov-04 Dec-04 Jan-05 Feb-05 Mar-05 Apr-05 May-05 Jun-05 Jul-05 Aug-05 Sep-05 Oct-05 Nov-05 Dec-05 Mar-06 Jun-06 Figure 2. Serial results of alanine aminotransferase (ALT), albumin and total daily protein loss (TDPL) with lamivudine treatment. J Formos Med Assoc 2007 Vol 106 No ALT (U/L)
4 T.W. Chuang, et al presence of immune complex deposits on kidney biopsy, and by the demonstration of glomerular deposits containing one or more HBV-related antigens (HBsAg and hepatitis B core antigen) on immunohistochemical study. In our patient, although special stains of HBV antigen was not performed, we used electron microscopy and found viral-like particles appearing as clusters of round to ovoid structures of nm in diameter and varying density distributed within the glomerular capillary basement membrane. In addition, active HBV infection during the course of disease progression and evidence of the reversibility of the renal disease concomitant with a decrease in viral load suggested a direct link between MN and HBV infection. The clinical manifestations of HBV-associated MN in pediatric and adult patients tend to be different. Pediatric chronic HBV carriers are not infrequently asymptomatic and HBV-associated nephropathy is detected by routine urine and serologic screening. 5 Unlike childhood disease in which there is a high rate of spontaneous remission, 2 adults with HBV-associated MN typically develop a progressive disease. 3 Therefore, there is a pressing need to develop an effective treatment for the latter. To date, the most experience with antiviral treatment for HBV-associated MN in adults has been limited to trials with IFN, and the results have been disappointing in Chinese subjects. 3,6 8 Furthermore, some disadvantages of IFN include its expense, the requirement for subcutaneous injection, and frequent side effects such as fever, headache, malaise, myalgia, as well as blood dyscrasias and neuropsychiatric disturbance. In contrast, the incidence of adverse effects with lamivudine is considered to be similar to that of placebo. Lamivudine therapy is safe and effective in chronic hepatitis B patients in terms of HBV DNA suppression, ALT normalization and improvement in histology. 9 Lamivudine treatment has been successful in adults with HBV-associated polyarteritis nodosa and other immune complex diseases. 10,11 Recently, a few case reports and only one cohort study with small case numbers have shown that lamivudine treatment might remit HBV-associated MN successfully In our patient, normalization of ALT levels and HBeAg seroconversion developed 2 months after the start of treatment, and nephrotic symptoms such as leg edema disappeared after 6 months of therapy. His daily urine protein excretion decreased from 6 g at baseline to 0.6 g by the end of treatment, and this continued to improve to the end of the follow-up period (0.02 g/ day). The response in our patient is comparable to that seen in other previously reported cases, suggesting that recovery of nephrosis takes a longer time than hepatitis activity in HBV-associated MN On the other hand, in contrast to childhood disease in which there is a rapid remission of proteinuria, adults with HBV-associated MN recover slowly Although lamivudine therapy successfully remitted the HBV-related membrane nephropathy, several issues need to be further clarified. First, the duration of lamivudine therapy remains unresolved. It is reasonable to maintain patients on long-term lamivudine treatment because of the high relapse rate on a short course. 17 Second, a potential limitation of prolonged treatment with lamivudine is the emergence of drug-resistant strains due to the induction and selection of HBV variants with mutations at the tyrosinemethionine-aspartate-aspartate (YMDD) motif of DNA polymerase. 18 One agent that might be considered in case of lamivudine resistance is adefovir dipivoxil, which is effective against both lamivudine-resistant HBV mutants as well as wildtype HBV. 19 However, this agent is potentially nephrotoxic and there are no data on its efficacy in HBV-related MN. Third, whether lamivudine therapy is helpful in HBV-related MN cases in which ALT levels are normal and there is no hepatitis activity or hepatitis B viremia remains unclear. Further studies in a larger cohort of patients are needed to clarify these important issues. References 1. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004;24: J Formos Med Assoc 2007 Vol 106 No 10
5 Lamivudine for HBV nephrotic syndrome 2. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 1994;8: Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: Cacoub P, Saadoun D, Bourliere M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 2005; 43: Lai KN, Lai FM, Tam JS, et al. High prevalence of hepatitis B surface antigenaemia in nephrotic syndrome in Hong Kong. Ann Trop Paediatr 1989;9: Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47: Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Longterm outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109: Abbas NA, Pitt MA, Green AT, et al. Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Nephrol Dial Transplant 1999;14: Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39:S Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001;344: Bedani PL, Bergami M, Cavazzini PL, et al. HBV-related cutaneous periarteritis nodosa in a patient 16 years after renal transplantation: efficacy of lamivudine. J Nephrol 2001; 14: Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: Okuse C, Yotsuyanagi H, Yamada N, et al. Successful treatment of hepatitis B virus associated membranous nephropathy with lamivudine. Clin Nephrol 2006;65: Kanaan N, Horsmans Y, Goffin E. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol 2006;65: Connor FL, Rosenberg AR, Kennedy SE, et al. HBV associated nephrotic syndrome: resolution with oral lamivudine. Arch Dis Child 2003;88: Filler G, Feber J, Weiler G, et al. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine. Arch Dis Child 2003;88: Lee CM, Ong GY, Lu SN, et al. Durability of lamivudineinduced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37: Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19: Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32: J Formos Med Assoc 2007 Vol 106 No
Xi Yang, Ri-Bao Wei, Ping Li, Yue Yang, Ting-Yu Su, Yu-Wei Gao, Qing-Ping Li, Xue-Guang Zhang, Xiang-Mei Chen
Int J Clin Exp Pathol 2016;9(9):9401-9407 www.ijcep.com /ISSN:1936-2625/IJCEP0028098 Original Article Correlation between serum hepatitis B virus DNA replication level and clinicopathology in 235 patients
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationChronic Active Hepatitis B with HBV- Associated Nephropathy: Close Resemblance to Lupus Nephritis
Chronic Active Hepatitis B with HBV- Associated Nephropathy: Close Resemblance to Lupus Nephritis Amitesh Aggarwal a, Mukul P. Agarwal a, Surendra Rajpal a, Vineeta V. Batra b, Ankit Kumar Sahu a a Department
More informationGlomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin
Glomerular Pathology- 1 Nephrotic Syndrome Dr. Nisreen Abu Shahin The Nephrotic Syndrome a clinical complex resulting from glomerular disease & includes the following: (1) massive proteinuria (3.5 gm /day
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationMr. I.K 58 years old
Mr. I.K 58 years old Hospitalized because of marked pitting peripheral edema (bilateral crural and perimalleolar edema) and uncontrolled blood pressure (BP 150/100 mmhg under treatment). since age 54 years
More informationDurability Of Lamivudine Associated HBe Antigen Seroconversion in Chinese-Canadian Patients with Chronic Hepatitis B Virus Infection
ISPUB.COM The Internet Journal of Gastroenterology Volume 4 Number 2 Durability Of Lamivudine Associated HBe Antigen Seroconversion in Chinese-Canadian Patients with Chronic Hepatitis B Virus Infection
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated Interferon alfa 2a, 180 mcg for subcutaneous injection (Pegasys ) No. (186/05) Roche New indication (chronic hepatitis B) 10 June 2005 The Scottish Medicines Consortium
More informationCHAPTER 2. Primary Glomerulonephritis
2nd Report of the PRIMARY GLOMERULONEPHRITIS CHAPTER 2 Primary Glomerulonephritis Sunita Bavanandan Lee Han Wei Lim Soo Kun 21 PRIMARY GLOMERULONEPHRITIS 2nd Report of the 2.1 Introduction This chapter
More informationChronic hepatitis B virus (HBV) infection remains a major
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:541 545 Hepatitis B Virus DNA Level Predicts Hepatic Decompensation in Patients With Acute Exacerbation of Chronic Hepatitis B WEN JUEI JENG, I SHYAN SHEEN,
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationJournal of Nephropathology
www.nephropathol.com DOI: 10.15171/jnp.2018.22 J Nephropathol. 2018;7(2):93-97 Journal of Nephropathology Anti-phospholipase A2 receptor antibody positive hepatitis B virus-associated membranous nephropathy
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationTherapeutic Guidelines on Management of Chronic Hepatitis B in Asia
SPECIAL FEATURE Vol.6 No.2 (April 2001) Therapeutic Guidelines on Management of Chronic Hepatitis B in Asia Abstract Dr. Nancy Leung Department of Medicine and Therapeutics, Prince of Wales Hospital, The
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationTherapy With Interferon-α Plus Ribavirin for Membranoproliferative Glomerulonephritis Induced by Hepatitis C Virus
BJID ; 7 (October) 5 Therapy With Interferon-α Plus Ribavirin for Membranoproliferative Glomerulonephritis Induced by Hepatitis C Virus Edmundo P.A. Lopes, Lucila M. Valente, Divisions of Gastroenterology
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationEmerging Drug List ADEFOVIR DIPIVOXIL FOR HEPATITIS B VIRUS INFECTION NO. 48 SEPTEMBER Generic (Trade Name): Adefovir dipivoxil (Hepsera TM )
Generic (Trade Name): Manufacturer: Adefovir dipivoxil (Hepsera TM ) Gilead Sciences, Inc. NO. 48 SEPTEMBER 2003 Indication: Current Regulatory Status: For the treatment of adults showing evidence of active
More informationDr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing proteinuria & haematuria Highlight diagnostic pitfalls Nephrotic
More informationRENAL HISTOPATHOLOGY
RENAL HISTOPATHOLOGY Peter McCue, M.D. Department of Pathology, Anatomy & Cell Biology Sidney Kimmel Medical College There are no conflicts of interest. 1 Goals and Objectives! Goals Provide introduction
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationHepatitis B virus infection. Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital
Hepatitis B virus infection Chow Wan Cheng Dept of Gastroenterology & Hepatology Singapore General Hospital Chronic Hepatitis B - are we in the same situation as hepatitis C? Treatment of chronic hepatitis
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationA Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis B
C linical S tudy Janardan Singh* Anupam Chakraborty* Mukul Chandra Dhar* Sudhakaran C** Mitra SK** A Preliminary Study on the Safety and Efficacy of HD-03/ES Therapy in Patients with Chronic Hepatitis
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationA clinical syndrome, composed mainly of:
Nephritic syndrome We will discuss: 1)Nephritic syndrome: -Acute postinfectious (poststreptococcal) GN -IgA nephropathy -Hereditary nephritis 2)Rapidly progressive GN (RPGN) A clinical syndrome, composed
More informationDense deposit disease with steroid pulse therapy
Case Report Dense deposit disease with steroid pulse therapy Jun Odaka, Takahiro Kanai, Takane Ito, Takashi Saito, Jun Aoyagi, and Mariko Y Momoi Abstract Treatment of dense deposit disease DDD has not
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationGlomerular pathology-2 Nephritic syndrome. Dr. Nisreen Abu Shahin
Glomerular pathology-2 Nephritic syndrome Dr. Nisreen Abu Shahin 1 The Nephritic Syndrome Pathogenesis: inflammation proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationIntron A HEPATITIS B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.01 Subject: Intron A Hepatitis B Page: 1 of 8 Last Review Date: September 18, 2015 Intron A HEPATITIS
More informationCrescentic Glomerulonephritis (RPGN)
Crescentic Glomerulonephritis (RPGN) Background Rapidly progressive glomerulonephritis (RPGN) is defined as any glomerular disease characterized by extensive crescents (usually >50%) as the principal histologic
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationGlomerular diseases mostly presenting with Nephritic syndrome
Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationInteresting case seminar: Native kidneys Case Report:
Interesting case seminar: Native kidneys Case Report: Proximal tubulopathy and light chain deposition disease presented as severe pulmonary hypertension with right-sided cardiac dysfunction and nephrotic
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationChallenges in therapy of chronic hepatitis B
Journal of Hepatology 39 (2003) S230 S235 www.elsevier.com/locate/jhep Challenges in therapy of chronic hepatitis B Jay H. Hoofnagle* Division of Digestive Diseases and Nutrition, National Institute of
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationGOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS
GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS VESNA JURČIĆ 1, ANDREJA ALEŠ RIGLER 2, INSTITUTE OF PATHOLOGY, FACULTY OF MEDICINE, UNIVERSITY
More informationHepatitis B and Renal Disease
Curr Hepatitis Rep (2010) 9:99 105 DOI 10.1007/s11901-010-0042-6 Hepatitis B and Renal Disease Tak Mao Chan Published online: 14 April 2010 # The Author(s) 2010. This article is published with open access
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationHepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization
More informationTHE URINARY SYSTEM. The cases we will cover are:
THE URINARY SYSTEM The focus of this week s lab will be pathology of the urinary system. Diseases of the kidney can be broken down into diseases that affect the glomeruli, tubules, interstitium, and blood
More informationCase Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features
Hindawi Case Reports in Nephrology Volume 2017, Article ID 1027376, 5 pages https://doi.org/10.1155/2017/1027376 Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationTHE URINARY SYSTEM. The cases we will cover are:
THE URINARY SYSTEM The focus of this week s lab will be pathology of the urinary system. Diseases of the kidney can be broken down into diseases that affect the glomeruli, tubules, interstitium, and blood
More informationCHAPTER 2 PRIMARY GLOMERULONEPHRITIS
CHAPTER 2 Sunita Bavanandan Lim Soo Kun 19 5th Report of the 2.1: Introduction This chapter covers the main primary glomerulonephritis that were reported to the MRRB from the years 2005-2012. Minimal change
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationManagement of chronic hepatitis B
Journal of Hepatology 38 (2003) S90 S103 www.elsevier.com/locate/jhep Management of chronic hepatitis B Hari S. Conjeevaram, Anna Suk-Fong Lok* Division of Gastroenterology, University of Michigan Medical
More informationResearch Article Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B
Gastroenterology Research and Practice Volume 2015, Article ID 126532, 6 pages http://dx.doi.org/10.1155/2015/126532 Research Article Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause
More informationPathological Features and Prognosis in Chronic Hepatitis B Virus Carriers
The Journal of International Medical Research 2011; 39: 71 77 Pathological Features and Prognosis in Chronic Hepatitis B Virus Carriers ZH LU, W CHEN, ZC JU, H PEI, XJ YANG, XB GU AND LH HUANG Department
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationC1q nephropathy the Diverse Disease
C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining
More informationcasebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach
casebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach In order to receive credit for this activity, please complete the post-test by recording the best answer to each question
More informationPros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:91 98 DOI 10.1007/s11901-010-0041-7 Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B Milan J. Sonneveld & Harry L. A. Janssen
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationViral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E
Viral hepatitis The word hepatitis means inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused by ingestion of contaminated food or
More information